title: CD52 expression patterns in myeloma and the applicability of alemtuzumab therapy.
abstract: Alemtuzumab has been proposed as a therapeutic agent in myeloma. CD52 was detected on plasma cells in 46/106 patients but levels were 30-fold lower than on alemtuzumab-responsive cells (n=138) and 8-fold lower than on alemtuzumab-resistant cells (n=57). The data suggest that myeloma plasma cells are unlikely to be depleted by alemtuzumab in most patients.
authors.forename: Andy C
authors.initials: AC
authors.lastname: Rawstron
authors.forename: Giles
authors.initials: G
authors.lastname: Laycock-Brown
authors.forename: Geoff
authors.initials: G
authors.lastname: Hale
authors.forename: Faith E
authors.initials: FE
authors.lastname: Davies
authors.forename: Gareth J
authors.initials: GJ
authors.lastname: Morgan
authors.forename: J Anthony
authors.initials: JA
authors.lastname: Child
authors.forename: Peter
authors.initials: P
authors.lastname: Hillmen
authors.forename: Roger G
authors.initials: RG
authors.lastname: Owen
mesh_terms: D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000627:therapeutic use*; D015703:Antigens, CD / Q000096:biosynthesis* / Q000235:genetics*; D000951:Antigens, Neoplasm / Q000096:biosynthesis* / Q000235:genetics*; D000074301:CD52 Antigen; D015972:Gene Expression Regulation, Neoplastic / Q000276:immunology; D006023:Glycoproteins / Q000096:biosynthesis* / Q000235:genetics*; D006801:Humans; D009101:Multiple Myeloma / Q000235:genetics / Q000378:metabolism* / Q000628:therapy*
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D015703:Antigens, CD; D000951:Antigens, Neoplasm; D000074301:CD52 Antigen; C000613862:CD52 protein, human; D006023:Glycoproteins; D000074323:Alemtuzumab